non-small cell lung cancer
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.
AbbVie's Telisotuzumab Vedotin Effective in NSCLC Patients With High, Intermediate c-MET Expression
Premium
The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Digital Pathology Test Predicts NSCLC Patients' Response to AstraZeneca, Daiichi Sankyo's Dato-DXd
Premium
A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.
Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.